3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
4
Neoplasms
3
Breast Neoplasms
3
Ovarian Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Neurofibromatoses
1
Neoplastic Cells, Circulating
1
Neoplasm Metastasis
1
Melanoma
1
Liver Neoplasms
1
Kidney Neoplasms
1
Hydrocephalus
1
Headache
1
Gallbladder Neoplasms
1
Female Breast Carcinoma
1
Epilepsy
1
Disease Progression
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Brain Edema
1
Abdominal Neoplasms
1
Interventions
Brentuximab Vedotin
3
relmacabtagene autoleucel
2
fludarabine phosphate
2
fludarabine
2
Cytarabine
2
Bortezomib
2
Antilymphocyte Serum
2
xihuang
1
tocilizumab
1
tislelizumab
1
sofosbuvir-velpatasvir drug combination
1
sintilimab
1
rasburicase
1
ledipasvir
1
entecavir
1
apatinib
1
aflibercept
1
acalabrutinib
1
Urate Oxidase
1
Trabectedin
1
Thiotepa
1
Thalidomide
1
Tenofovir
1
Tamsulosin
1
Sofosbuvir
1
Sevoflurane
1
Rivaroxaban
1
Ribavirin
1
Radiotherapy
1
Radiosurgery
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Recurrence
×
Sevoflurane
×
Clear all
NCT06330038
2026-04-20
GASTIVA
Samsung Medical Center
Phase 4
Recruiting
5,384 enrolled